Vulvar cancer overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 21: Line 21:
Screening for vulvar cancer is not recommended.<ref> What Should I Know About Screening? Gynecologic Cancers. http://www.cdc.gov/cancer/vagvulv/basic_info/screening.htm  Accessed on September 30, 2015</ref>
Screening for vulvar cancer is not recommended.<ref> What Should I Know About Screening? Gynecologic Cancers. http://www.cdc.gov/cancer/vagvulv/basic_info/screening.htm  Accessed on September 30, 2015</ref>


If left untreated, patients with vulvar cancer may progress to develop ulcer on vulva or wart-like patches on vulva, chronic puritius of the vulva and lichenification. Common complications of vulvar cancer
If left untreated, patients with vulvar cancer may progress to develop [[ulcer]] on vulva or wart-like patches on vulva, chronic [[pruritus]] of the vulva and lichenification. Common complications of vulvar cancer include  fistula and [[metastasis]]. Prognosis is generally good, and the 5 year survival rate of patients with vulvar cancer is approximately 71.2%.
include  fistula and metastasis. Prognosis is generally good, and the 5 year survival rate of patients with vulvar cancer is approximately 71.2%.
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Gynecology]]
[[Category:Gynecology]]

Revision as of 20:11, 1 October 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [2]

Vulvar cancer Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Vulvar cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Vulvar cancer overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Vulvar cancer overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Vulvar cancer overview

CDC on Vulvar cancer overview

Vulvar cancer overview in the news

Blogs on Vulvar cancer overview

Directions to Hospitals Treating Vulvar cancer

Risk calculators and risk factors for Vulvar cancer overview

Overview

Vulvar cancer accounts for about 5% of cancers of the female genital system in the United States. The vulva is the area immediately external to the vagina, including the mons pubis, labia, clitoris, Bartholin glands, and perineum. The labia majora are the most common site of vulvar carcinoma involvement and account for about 50% of cases. The labia minora account for 15% to 20% of vulvar carcinoma cases. The clitoris and Bartholin glands are less frequently involved. Lesions are multifocal in about 5% of cases. About 90% of vulvar carcinomas are squamous cell cancers. The vulvar intraepithelial neoplasias (VIN), may be precursors to invasive squamous cell cancers.[1]

Classification

Vulvar cancer may be classified according to histology into 3 groups: vulvar carcinoma, vulvar sarcoma and vulvar malignant melanoma.[2]

Pathophysiology

Development of vulvar cancer is the result of multiple genetic mutations.

Causes

Vulvar cancer may be caused by either HPV infection, or vulvar dermatoses.

Differential Diagnosis

Vulvar cancer must be differentiated from other neoplastic vulvar lesions, non neoplastic vulvar lesions and infectious disease lesions of vulva.

Epidemiology and Demographics

In 2012, the incidence of vulvar cancer was estimated to be 2.4 per 100,000 females in the United States. The incidence of vulvar cancer increases with age, the median age at diagnosis is 68 years and it is more prevalent in the white race.[3]

Risk factors

Common risk factors in the development of vulvar cancer are human papilloma virus, human immunodeficiency virus, vulvar intraepithelial neoplasia, and lichen sclerosus.[4]

Screening

Screening for vulvar cancer is not recommended.[5]

If left untreated, patients with vulvar cancer may progress to develop ulcer on vulva or wart-like patches on vulva, chronic pruritus of the vulva and lichenification. Common complications of vulvar cancer include fistula and metastasis. Prognosis is generally good, and the 5 year survival rate of patients with vulvar cancer is approximately 71.2%.

References

  1. General Information About Vulvar Cancer. National Cancer Institute. http://www.cancer.gov/types/vulvar/hp/vulvar-treatment-pdq Accessed on october 1, 2015
  2. Hoffman, Barbara (2012). Williams gynecology. New York: McGraw-Hill Medical. ISBN 9780071716727.
  3. SEER Stat Fact Sheets: Vulvar Cancer. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/statfacts/html/vulva.html Accessed on September 21, 2015
  4. Risk factors for vulvar cancer. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/vulvar/risks/?region=ns Accessed on September 27, 2015
  5. What Should I Know About Screening? Gynecologic Cancers. http://www.cdc.gov/cancer/vagvulv/basic_info/screening.htm Accessed on September 30, 2015